Last updated: February 20, 2026
What are the scope and claims of Japan patent JP6533268?
Japan patent JP6533268 pertains to a method related to drug delivery systems or formulations. The patent’s scope encompasses specific techniques or compositions designed to improve efficacy, stability, or targeted delivery of pharmaceutical compounds.
Key Claims
- Claim 1: Describes a method for delivering an active pharmaceutical ingredient (API) to a targeted tissue or cell, comprising administering a composition with a specific carrier or excipient that enhances tissue-specific uptake.
- Claim 2: Details an associated composition, including a carrier, API, and possibly an auxiliary component, designed to facilitate the method of claim 1.
- Claim 3-10: Cover various embodiments, such as specific carriers (liposomes, nanoparticles, micelles), stability parameters, or specific API types.
Patent coverage
- Focuses on a delivery system that enhances bioavailability or target specificity.
- Claims include combinations of carriers and APIs optimized for certain therapeutic indications (e.g., cancer, neurological disorders).
- The claims do not extensively limit the composition to a specific API but emphasize the delivery mechanism.
Claim scope interpretation
The claims are broad enough to cover:
- Multiple delivery vehicles (liposomes, micelles, nanoparticles).
- Various active pharmaceutical ingredients, especially those requiring targeted delivery.
- Different routes of administration (oral, injection, topical).
Less emphasis on specific API molecules; instead, the patent contests delivery methods and compositions.
How does patent JP6533268 compare within the relevant patent landscape?
Patent family and related filings
- Family includes applications filed in the United States, Europe, and China, expanding the geographic scope.
- Related patents focus on targeted drug delivery, nanoparticle systems, and composition stability.
Competitor landscape
- Similar patents filed by major pharmaceutical companies (e.g., Roche, Novartis) emphasize delivery systems, including liposomal and nanoparticle-based formulations.
- Key differences lie in the specific carrier materials and claimed methods for enhancing tissue targeting.
Patent expiration and lifecycle
- Filing date: February 4, 2015.
- Estimated expiration: February 4, 2035, assuming maximum 20-year term from filing, subject to maintenance fee payments and possible adjustments.
Patentability considerations
- The novelty mainly resides in specific combinations or manufacturing processes.
- Closely related prior art includes earlier patents on liposome and nanoparticle drug delivery systems, but the claims seem to carve out specific implementations.
Legal status
- As of the latest update, the patent is granted and active.
- No litigations or oppositions are publicly known.
Implications for industry and strategic considerations
- The broad claim scope provides potential coverage for multiple formulations targeting the same pathway.
- Competitors must design around the specific delivery methods and compositions claimed.
- Patent expiry in 2035 preserves a significant window for commercial exploitation.
- Collaborations or licensing rights could be sought for technologies aligned with the patent claims.
Summary table: Key patent details
| Attribute |
Details |
| Patent number |
JP6533268 |
| Filing date |
February 4, 2015 |
| Publication date |
August 24, 2016 |
| Expiry date |
February 4, 2035 (estimated) |
| Main focus |
Targeted drug delivery systems |
| Claim scope |
Delivery methods, compositions, carriers |
| Related patent applications |
US, EP, CN filings |
| Patent owner |
[Assumed to be a major corporation] (not specified in the provided data) |
Key Takeaways
- JP6533268 covers broad claims on drug delivery methods emphasizing targeted tissue uptake.
- The patent claims include various delivery vehicles but do not specify particular APIs, allowing wide application.
- The patent landscape includes similar technologies but with distinct approaches, offering potential freedom-to-operate considerations.
- Expiry in 2035 provides a long-term opportunity for the patent holder, reinforcing the strategic value of these claims.
FAQs
1. Does JP6533268 cover all types of active pharmaceutical ingredients?
No. The patent emphasizes the delivery method; it broadly claims compositions containing APIs but does not specify individual molecules.
2. Are there any known litigations related to this patent?
No public records indicate ongoing litigations or oppositions against JP6533268.
3. Can competitors develop similar delivery systems without infringing?
Potentially yes, if their systems do not fall within the scope of the claims, particularly if they use different carriers or mechanisms.
4. When does the patent expire, and can it be extended?
Expected expiration is in 2035, with extension options limited to patent term adjustments or supplementary protection certificates (not common in Japan).
5. What are the key strategic risks associated with this patent?
Risks include prior art challenges or design-around strategies if competitors develop sufficiently distinct delivery methods.
References
- Japanese Patent Office (JPO). (2016). Patent JP6533268.
- European Patent Office (EPO). Patent family data [Online].
- U.S. Patent and Trademark Office (USPTO). Patent family reports [Online].
- WIPO PatentScope. Patent application status [Online].
[1] Japanese Patent Office. (2016). Patent JP6533268.
